Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Proactively manage your pharmacy inventory
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives|
|Abstract:||6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.|
|Inventor(s):||Krenitsky; Thomas A. (Chapel Hill, NC), Averett; Devron R. (Raleigh, NC), Koszalka; George W. (Chapel Hill, NC), Wolberg; Gerald (Cary, NC)|
|Assignee:||Burroughs Wellcome Co. (141) (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9015914||Jul 19, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||151637||<disabled in preview>|
|Australia||641533||<disabled in preview>|
|Australia||8196091||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.